Filgrastim BS F / Mochida
Filgrastim biosimilar developed by Fuji Pharma (with Mochida). Reference product Neupogen.
About Filgrastim BS F / Mochida
Filgrastim BS F was the first filgrastim biosimilar approved in Japan, in November 2012, developed by Fuji Pharma and also sold under Mochida's name. The Mochida version has since been discontinued. The Japanese reference product is Gran.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan · Filgrastim BS F / Mochida
Pharmaceuticals and Medical Devices Agency and MHLWApprovedCanada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Filgrastim BS F / Mochida holds an approval, these are the other filgrastim biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| PMDA | 2 | Nippon Kayaku (Filgrastim BS NK), Sandoz (Zarxio / Zarzio) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Fuji Pharma: Aflibercept BS NIT, Denosumab BS F, Golimumab BS F, Ustekinumab BS F.
Chronology
- PMDANov 2012Approved by MHLW
Sources
S020PMDA, list of approved biosimilar products in Japan (as of July 2026) Primary (regulator)
Planning filgrastim biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant